218 reports of this reaction
1.6% of all EMTRICITABINE reports
#13 most reported adverse reaction
PATHOGEN RESISTANCE is the #13 most commonly reported adverse reaction for EMTRICITABINE, manufactured by Gilead Sciences, Inc.. There are 218 FDA adverse event reports linking EMTRICITABINE to PATHOGEN RESISTANCE. This represents approximately 1.6% of all 13,674 adverse event reports for this drug.
Patients taking EMTRICITABINE who experience pathogen resistance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PATHOGEN RESISTANCE is a less commonly reported adverse event for EMTRICITABINE, but still significant enough to appear in the safety profile.
In addition to pathogen resistance, the following adverse reactions have been reported for EMTRICITABINE:
The following drugs have also been linked to pathogen resistance in FDA adverse event reports:
PATHOGEN RESISTANCE has been reported as an adverse event in 218 FDA reports for EMTRICITABINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PATHOGEN RESISTANCE accounts for approximately 1.6% of all adverse event reports for EMTRICITABINE, making it a notable side effect.
If you experience pathogen resistance while taking EMTRICITABINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.